Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott AndroGel 1.62% gets FDA approval
AndroGel (testosterone gel) 1.62% is a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose
AndroGel (testosterone gel) 1.62% is a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose
For the first quarter of 2011, the company reported a net income of $1.07bn, compared to $330m for the same period in 2010. Merck’s worldwide sales were $11.6bn
The trial is intended to establish if Multikine administered prior to current standard of care (surgery plus radiotherapy or surgery plus concurrent chemo radiotherapy) in previously untreated subjects
The company has posted a net income of $255.08m, compared to $234.44m for the same period in 2010. For the first quarter of 2011, Celgene‘s operating income was
IDT is the supplier of custom nucleic acids in the US, serving academic, government and commercial researchers in biotechnology, clinical diagnostics and pharmaceutical development. The novel proprietary probe
The Phase IIb trial was originally started in July 2009 and involves a two-year follow up on the infants vaccinated as part of the trial to investigate whether
ZYTIGA is an oral androgen biosynthesis inhibitor that inhibits androgen producing CYP17 enzyme complex. According to a randomized, placebo-controlled Phase 3 study treatment with ZYTIGA in combination with
The company has posted net income of $8.41m, as compared to net income of $8.91m for the year ago period. China Pharma’s income from operations was $10.42m for
The MLSC grant amount is $250,000 per year for two years, and subject to a formalized agreement between the parties, will be matched dollar for dollar by RXi,
ORAL Standard is a completed 12 month study in patients with moderate-to-severe active RA who had an inadequate response to methotrexate (MTX) and were randomized to receive tofacitinib